On 27 August, scientists from the ROADMAP project published a literature review of studies that analysed decisions in HTAs in the journal Cambridge University Press. The literature review focusses on decisions made across disease areas in three European countries (England, Germany, and The Netherlands). The team carried out case studies of technology assessments that were conducted for Alzheimer’s disease (AD) drugs in these countries.
In their paper, the researcher’s report that they found that outcomes measured using clinical scales had an overall stronger influence on decisions respectively recommendations about whether or not to fund AD drugs. Furthermore, they add that processes did not include early discussion and agreement on what would constitute appropriate outcome measures and cut-off points for effects. The article can be found here: https://doi.org/10.1017/S0266462320000574
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
